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ABSTRACT
This study sought to identify critical determinants of mesenchymal stem cell (MSC) potency
using in vitro and in vivo attributes of cells isolated from the bone marrow of age- and sex-
matched donors. Adherence to plastic was not indicative of potency, yet capacity for long-term
expansion in vitro varied considerably between donors, allowing the grouping of MSCs from the
donors into either those with high-growth capacity or low-growth capacity. Using this grouping
strategy, high-growth capacity MSCs were smaller in size, had greater colony-forming efﬁciency,
and had longer telomeres. Cell-surface biomarker analysis revealed that the International Soci-
ety for Cellular Therapy (ISCT) criteria did not distinguish between high-growth capacity and
low-growth capacity MSCs, whereas STRO-1 and platelet-derived growth factor receptor alpha
were preferentially expressed on high-growth capacity MSCs. These cells also had the highest
mean expression of the mRNA transcripts TWIST-1 and DERMO-1. Irrespective of these differen-
ces, both groups of donor MSCs produced similar levels of key growth factors and cytokines
involved in tissue regeneration and were capable of multilineage differentiation. However, high-
growth capacity MSCs produced approximately double the volume of mineralized tissue com-
pared to low-growth capacity MSCs when assessed for ectopic bone-forming ability. The addi-
tional phenotypic criteria presented in this study when combined with the existing ISCT
minimum criteria and working proposal will permit an improved assessment of MSC potency
and provide a basis for establishing the quality of MSCs prior to their therapeutic application.
STEM CELLS 2015;33:1878–1891
INTRODUCTION
Potency assays that predict the therapeutic
efﬁcacy of bone marrow-derived adult mesen-
chymal stem cells (MSCs) are critical to their
successful application in regenerative medi-
cine. Patients are still currently receiving cells
of unproven potency, which in turn, may con-
tribute to many of the suboptimal outcomes
that are being reported [1]. Even in cases
where MSC therapy has proven beneﬁcial, use
of cells with higher potency may result in
improved efﬁcacy.
However, despite a considerable body of
research over the last decade, resulting in an
increasing pace of investigational new drug
(IND) submissions to the U.S. FDA, there is still
no generally accepted deﬁnition of what con-
stitutes a mesenchymal stem (or stromal) cell
[2, 3]. In view of the growing clinical utility of
MSCs, there is a pressing need to develop bet-
ter standards that more accurately establish
their potency. These standards should be
broadened beyond those originally nominated
by the International Society for Cellular Ther-
apy (ISCT) [4] that are proving insufﬁcient pre-
dictors of therapeutic success, even though
this may not have been their intended use.
For example, other notable criteria that
include paracrine factors [5] as well as immu-
nomodulatory status [6, 7] need to be consid-
ered. The need for better reference standards
for MSCs was also recently emphasized by
Prockop et al. [8].
The problem in establishing such bench-
marks is that MSCs consist largely of heteroge-
neous subpopulations of adherent cells that
are typically isolated from adult bone marrow
that, when induced, are capable of self-
renewal, colony formation, and multilineage
differentiation [9–12]. However, the ability of
MSCs to survive and differentiate in vitro has
proven a poor predictor of their ability to
repair tissue [13–15]. Efforts to increase MSC
potency by deriving populations from single
cells have failed to increase the proportion of
MSCs in the subsequent population of pas-
saged cells [16]. Also, strategies for enriching
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MSCs exploiting one or more cell-surface markers have gained
favor, particularly for markers such as stromal precursor
antigen-1 (STRO-1) [17, 18], SSEA-4 [19], CD49a [20], CD271
[21], CD146 [22], leptin receptor [23], and the use of size-
sorting from adherent cultures of bone marrow aspirates [11,
24]. Yet these enriched MSCs still require extensive expansion
prior to reimplantation or banking that may result in a subse-
quent increase in cell heterogeneity and a presumptive
decrease in potency.
Another characteristic of MSCs gaining attention is the
trophic factors they produce [5, 25]. Vascular endothelial
growth factor (VEGF) has been shown to play crucial roles in
the repair of heart failure [26], hepatocyte growth factor
(HGF) in the amelioration of multiple sclerosis [27] and graft-
versus-host disease, and insulin-like growth factor (IGF-1) and
epidermal growth factor (EGF) in wound healing [28]. These
factors are thought to play critical roles in cell engraftment
and wound healing. Moreover, it may be possible to link MSC
potency directly to their secretory proﬁle [29, 30].
Here, we sought to identify critical determinants of MSC
potency by linking in vitro attributes such as self-renewal and
clonogenicity, cell size, telomere length, mRNA proﬁle, and
growth factor/cytokine secretion to in vivo tissue regeneration
ability as determined by their ectopic bone-forming ability.
This study highlights that the minimum criteria suggested by
the ISCT for deﬁning MSCs are not in themselves predictive of
stem cell potency. There is thus a need for common guide-
lines and protocols for the characterization of MSCs for clini-
cal use, as suggested in the ISCT working proposal [31].
Therefore, in an effort to improve MSC characterization, our
data suggest the need to include additional criteria when
assessing MSC functional potency which include the rate of
self-renewal, expression of the mRNA transcripts TWIST-1 and
DERMO-1, and the expression of the cell-surface biomarkers
STRO-1 and platelet-derived growth factor receptor alpha
(PDGFR-a).
MATERIALS AND METHODS
Isolation and Culture of MSCs
Human MSCs were isolated from the bone marrow of six
healthy donors with no reported antibiotic sensitivity (Sup-
porting Information Table S1) by plating human bone marrow
mononuclear cell (MNC) fractions (Lonza, Walkersville, MD,
www.lonza.com) in maintenance media comprising of Dulbec-
co’s Modiﬁed Eagle’s medium (DMEM) (DMEM-low glucose,
1,000 mg/l) with 10% fetal calf serum (Hyclone, Logan, UT,
www.hyclone.com), 2 mM L-glutamine, 50 U/ml penicillin, and
50 U/ml streptomycin (Sigma-Aldrich, St. Louis, MO, www.sig-
maaldrich.com), as described previously [32]. Brieﬂy, mononu-
clear cells were washed in maintenance media, centrifuged,
resuspended in media, and plated at a density of 50,000 cells
per square centimeter in T175 ﬂasks. Cells were allowed to
adhere for 7 days following which nonadherent cells were
removed and fresh media added. The plastic adherent cells
were cultured for 3 weeks, harvested, and counted (Support-
ing Information Fig. S1B) before replating them for expansion
at a density of 5,000 cells per square centimeter. Cells from
passage 4 were used for all experiments, unless otherwise
stated. Individual donor MSCs were characterized and experi-
mented on as separate MSC populations throughout, and
there was no parameter upfront that distinguished the plated
cells of different donors. For colony-forming units-ﬁbroblastic
(CFU-F) assays, MNCs were plated at 0.5–3.0 3 106 cells in
T75 ﬂasks, allowed to adhere and form colonies, and stained
with 0.5% crystal violet (Sigma-Aldrich) after 14 days. Visible
colonies were quantiﬁed only when they were greater than or
equal to 50 cells, and not in contact with an adjacent colony.
Efﬁciency was calculated by estimating the number of colonies
formed per 105 cells plated.
Cell-Size Analysis
Single-cell suspensions of MSCs were stained with Annexin V,
washed, and resuspended in MACS buffer (2 mM EDTA, 0.5%
bovine serum albumin (BSA) in PBS, pH 7.2) before analysis
using FACSArray Bioanalyzer (BD Biosciences, San Jose, CA,
www.bdbiosciences.com). After gating out Annexin V1 cells, a
quadrant gate was applied to the live population, and the
fraction of low forward scatter/side scatter (FSC/SSC) events
recorded to obtain the relative percentage of small-sized cells.
Cumulative Growth and Telomere Length Analysis
To assess MSC growth, cells were seeded at 5,000 cells per
square centimeter and cultured under maintenance condi-
tions. At 70%–80% conﬂuence, cells were enzymatically
removed with 0.125% trypsin/Versene and viable cells
counted using Guava EasyCyte Plus (Milipore, Merck KGaA,
Darmstadt, Germany, www.merckmillipore.com). Cells were
replated at the same density and progressively subcultured
for 13–15 passages (i.e., until senescence) to estimate cumu-
lative cell numbers and population doublings. Genomic DNA
at different passages was isolated and telomere length analy-
sis performed as described previously [33].
Flow Cytometry
Single-cell suspensions were stained with phycoerythrin- or
ﬂuorescein isothiocyanate-conjugated anti-human CD105
(266), CD73 (AD2), CD90 (5E10), CD45 (H130), CD34 (RAM34),
CD49a (SR84), CD29 (MAR4), EGF-R (EGFR.1), IGF-IRa (CD221,
1H7), NGF-R (CD271, C40–1457), PDGFR-a and b (CD140a,
aR1 and CD140b, 28D4), CD11b (D12), HLA-DR (TU36), CD19
(HIB19), CD14 (MaP9), CD106 (51-10C9), CD146 (P1H12),
SSEA-4 (MC813-70), STRO-1 antibodies or the isotype-
matched controls IgG1j (MOPC-21), IgG2aj (G155-178),
IgG2bj (27235), IgM, and IgG3 (A112-3), and analyzed on a
BD FACSArray Bioanalyzer and FlowJo software v8.0 (Tree Star,
Inc. Ashland, OR, http://www.ﬂowjo.com) by gating at 2% of
isotype control. For each marker and isotype, 20,000 events
were acquired. All antibodies were purchased from BD Bio-
sciences except IgM (l-chain speciﬁc) (Caltag laboratories, Bur-
lingame, CA, www.lifetechnologies.com) and STRO-1 (kindly
provided by Prof. Stan Gronthos, School of Medical Sciences,
Faculty of Health Sciences, University of Adelaide, Australia).
Immunomodulation Assay
All experiments using human blood were approved by the
Institutional Review Board at the National University of Singa-
pore (NUS-IRB 09-256) and comply with the Helsinki declara-
tion. Written informed consent was obtained from all blood
donors prior to blood collection. Adult human blood was col-
lected in BD K2 EDTA Vacutainers (Becton Dickinson, Franklin
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Lakes, NJ, www.bd.com) and PBMCs were isolated by Ficoll-
Paque PLUS (GE Healthcare, Freiburg, Germany, www.gelifes-
ciences.com) density gradient centrifugation (400 x g for 30
min without brake). CD41 T cells were isolated from PBMCs
using EasySep negative selection human CD41 T cell enrich-
ment kit (Stem Cell Technologies, Vancouver, BC, http://www.
stemcell.com) and labeled with 5 mM carboxy-ﬂuorescein diac-
etate succinimidyl ester (CFDA-SE kit, Life Technologies,
Molecular Probes, Carlsbad, CA, www.lifetechnologies.com).
CD41 CFSE1 cells (0.5–1 3 105) were stimulated by anti-CD3/
anti-CD28 MACSiBeads (Miltenyi Biotec, Bergisch Gladbach,
Germany, www.miltenyibiotec.com) at a ratio of four beads
per T cell, to which MSCs were added at different T cell/MSC
ratios and incubated at 37C. Proliferation of CD41 CFSE1
cells was measured after 7 days by ﬂow cytometry and the
percentage inhibition of T-cell proliferation determined.
Multiplex Detection of Growth Factors and Cytokines
Cells were cultured in maintenance media for 4 days and con-
ditioned media collected thereafter. To release matrix bound
proteins, cell layers were washed with 2 M NaCl in 20 mM
HEPES (pH 7.4) for 10 seconds. The conditioned media and
salt wash were analyzed separately using Human Cytokine/
Chemokine kit (MPXHCYTO-60K, Millipore) for simultaneous
quantiﬁcation of 14 growth factors and cytokines, according
to the manufacturer’s instructions. Results are presented as
logarithmic concentration for each analyte (growth factor or
cytokine), which includes factors bound to matrix as well as
secreted into media. Results are shown as mean of two indi-
vidual experiments for each donor.
Gene Expression Analysis
For quantitative PCR, total RNA was isolated using a Nucleo-
spin RNA II kit (Macherey Nagel, Bethlehem, PA, www.mn-net.
com) according to the manufacturer’s instructions and quanti-
ﬁed by NanoDrop 1000 (Thermo Fisher Scientiﬁc, Inc. Wil-
mington, DE, www.thermoﬁsher.com). After conversion to
cDNA (Superscript VILO, Life Technologies, Invitrogen, Carls-
bad, CA, www.lifetechnologies.com), expression of mesoder-
mal genes TWIST-1 and DERMO-1, osteogenic markers RUNX2,
ALP, and BSP-II, adipogenic markers PPARc and CEBPa, and
chondrogenic genes COL2A1 and SOX9 was assessed using
TaqMan Gene Expression assays on an Applied Biosystems
7500 PCR System (Life Technologies, Applied Biosystems,
Carlsbad, CA, www.lifetechnologies.com) (Supporting Informa-
tion Table S2). CT values were normalized to b-ACTIN and
results plotted as relative expression units.
For microarray, RNA extracted from MSCs was ampliﬁed
using a TotalPrep RNA ampliﬁcation kit according to the man-
ufacturer’s instructions (Life Technologies, Ambion, Grand
Island, NY, www.lifetechnologies.com). The resulting puriﬁed
biotin-labeled complementary RNA (cRNA) was normalized
and hybridized onto a HumanHT-12 version 4 beadchip (Illu-
mina, San Diego, CA, http://www.illumina.com) using direct
hybridization. The chip was then washed, blocked, and Cy3-
streptavidin bound to the hybridized cRNA. An Illumina Bea-
dArray Reader using the Illumina BeadScan software was used
to image the chip, and the image data converted into an
expression proﬁle by GenomeStudio (Illumina). After back-
ground subtraction, data were submitted to GeneSpring (Agi-
lient Technologies, Santa Clara, CA, www.agilent.com). The
replicates were averaged and pairwise analysis performed, fol-
lowed by a Student’s t test with p< .05 and fold change
1.5. Two donor samples representing each group with two
technical replicates were analyzed. The gene lists generated
were uploaded using Entrez gene ID onto DAVID (david.abcc.
ncifcrf.gov) for functional annotation clustering by
GOTERM_BP_FAT with medium classiﬁcation stringency [34].
Only biological processes with p .05 were considered.
Multilineage Differentiation
Evaluation of the differentiation potential of MSCs for osteo-
genic, adipogenic, and chondrogenic lineages was performed
as described previously [32]. Average intensities of stained
wells/pellets were quantiﬁed using Quantity One software
(Bio-Rad Laboratories, Hercules, CA, www.bio-rad.com). For
the von Kossa and oil red O methods, the staining intensity
values were normalized to DNA content. Results are
expressed as relative intensity per microgram DNA (fold-
increases of intensity in treatment wells compared to their
respective control wells; Supporting Information Fig. S4). In
these measurements, a darker stain implies a higher density
value.
Ectopic Bone Formation Assay
Comparison of in vivo efﬁcacy between individual MSC donors
was assessed by ectopic bone formation assay. The experi-
mental groups included MASTERGRAFT Matrix (Medtronic,
Minneapolis, MN, www.medtronic.com) alone (control) and
MASTERGRAFT Matrix with MSC from 6 individual donors
(donors A, B, C, D, E, and F) resulting in seven groups with 5
implants per group (35 implants in total). The implants were
randomly assigned to 18 mice, with up to 2 implants per ani-
mal. Donor MSCs at P4 (3 3 106 cells) were seeded onto
scaffolds before implantation into subcutaneous pockets of 8-
week-old immunodeﬁcient mice (NIH-bg-nu-xid, Harlan
Sprague-Dawley, Harlan Laboratories, Indianapolis, IN, www.
harlan.com), as described previously [35]. Surgeries were per-
formed according to the speciﬁcations of an ethics-approved
small animal protocol (IACUC: #110651). An incision of 1 cm
was created dorsally on either side of the vertebral column
and a subcutaneous pocket created by blunt dissection. One
implant was placed in each pocket and incisions closed with
surgical staples. X-rays were taken immediately postimplanta-
tion and again at 8 weeks using a Shimadzu MobileArt MUX-
101 Standard (Shimadzu MobileArt MUX-101 Standard, Tokyo,
Japan, www.shimadzu.com) and a D€URR MEDICAL-CR 35 VET
Image Plate Scanner D€URR MEDICAL-CR 35 VET Image Plate
Scanner, Vancouver, WA, www.im3vet.com). At sacriﬁce (8
weeks), implants were removed, digitally photographed (Nikon
D80), and imaged using a Skyscan 1076 mCT scanner (Skyscan,
Kontich, Belgium, www.skyscan.be/) under parameters previ-
ously reported [36]. Reconstructed images (three-dimensional)
and bone volume measurements were performed using
Mimics 14.0 software (Materialise, Leuven, Belgium, www.
materialise.com) after applying appropriate threshold settings.
After mCT analysis, implants were transferred to 10% neutral
buffered formalin under vacuum for 1 week, decalciﬁed, par-
afﬁn embedded, sectioned, and stained as previously reported
[36, 37]. Immunohistochemistry was also performed using pri-
mary antibodies to mouse osteocalcin (M188, 1:100, Takara
Bio, Shiga, Japan, www.takara-bio.com) and human
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osteocalcin (ab76690, 1:50, Abcam, Cambridge, MA, www.
abcam.com). Sections were washed and bound antibody
detected using the Immunopure ABC peroxidase staining kit
as per the manufacturer’s recommendations (Vector Laborato-
ries, Burlingame, CA, www.vectorlabs.com). In order to verify
antibody speciﬁcity, staining with secondary antibody alone
was performed on relevant control tissues (Supporting Infor-
mation Fig. S6). All stained sections were examined under a
Zeiss AxioImager (Z1) upright microscope (Zeiss, Thornwood,
NY, www.zeiss.com).
Statistical Analyses
Quantitative data were obtained in triplicates and reported as
mean6 SD, unless otherwise stated. Statistical analyses were
performed using Student’s t test (GraphPad Prism, GraphPad
Software, La Jolla, CA, www.graphpad.com), unless otherwise
stated, and p value< .05 was considered signiﬁcant.
RESULTS
MSC Variability in Colony Formation, Cell-Size,
and Growth
MSCs from multiple human donors are known to vary consid-
erably in their growth parameters. To assess this variability,
we examined aspirates from age- and sex-matched donors.
Bone marrow mononuclear cells from all donors adhered to
tissue culture plastic and gave rise to colonies that readily
expanded in culture (Fig. 1A; Supporting Information Fig.
S1A). Signiﬁcant donor variability in CFU-F efﬁciency was
observed, with donors A, C, and E having greater efﬁciency
(7.46 1.7) than donors B, D, and F (3.26 1.1) (p< .001) (Fig.
1B). Nevertheless, all donor MSCs, by virtue of their plastic-
adherence and colony formation, satisﬁed this aspect of the
ISCT criteria.
Donor MSCs were assessed for their cell size. MSC cul-
tures are known to contain a subpopulation of small, round
cells that are rapidly self-renewing (RS), usually identiﬁed by
ﬂow cytometry as low forward scatter (FSClo) and low side
scatter (SSClo) [11, 24, 38]. MSCs isolated from donors A, C,
and E, with greater colony-forming ability, had a signiﬁcantly
higher proportion of smaller-sized cells (74.4%) (FSClo/SSClo in
quadrant 1, Fig. 1C), compared with the proportion of
smaller-sized MSCs from donors B, D, and F (66.4%)
(p< .001). Donors with higher CFU-F efﬁciency also had a
higher proportion of small-sized cells (Figs 1B, 1C).
Long-term expansion without phenotypic change is a key
parameter of MSC quality. We next monitored cell growth for
extended periods (8–10 weeks) in culture. Notably, changes in
cumulative growth revealed signiﬁcant differences in the pro-
liferative potential of MSCs from the different donors after
seven passages (Fig. 1D). Donor C displayed the greatest
growth, with donor F showing the least (Fig. 1D) by passage
13. Cells from donors A, C, and E (high-growth capacity)
achieved 33% more cell numbers over this period compared
with donors B, D, and F (low-growth capacity) (p< .05). Thus,
we observed that changes in self-renewal capacity only
became evident upon long-term passaging with MSCs from all
donors having similar cumulative growth up to passage 6.
Therefore, the high-growth capacity MSCs seen here were
also smaller in size and produced more CFU-Fs than the low-
growth MSCs.
As telomeres are tightly linked to cell division, we next
assessed their status during the serial passaging of MSCs.
Analysis from the ﬁrst passage (P1) until no further prolifera-
tion was observed (P13–P15) revealed progressive decreases
in relative telomere length (Fig. 1E). The rate of telomere
shortening occurred in a linear fashion, as indicated by the
negative slope of the curves (Fig. 1E), albeit at different rates
as shown by the r2 value (Fig. 1F). Regression plots of donors
A, C, and E (high-growth capacity) showed substantially lower
regression (r2) values than donors B, D, and F (low-growth
capacity), indicating that the high-growth MSCs reduced their
telomeres at slower rates than low-growth MSCs. In addition,
low-growth MSCs failed to self-renew after only 13 passages,
whereas the high-growth capacity MSCs continued to prolifer-
ate until at least 15 passages. Collectively, our data show that
donor MSCs classiﬁed as having high-growth capacity had an
increased capacity for self-renewal, a higher CFU-F efﬁciency,
and a larger proportion of small-sized cells.
Immunophenotypic Profiles of MSCs
We next analyzed a set of 25 surface markers including those
described by the ISCT [4]. Culture-expanded MSCs from all
donors strongly expressed the MSC markers CD105, CD73,
and CD90 (greater than 95%) and were negative for the
hematopoietic markers CD45, CD34, CD11b, CD14, CD38,
CD19, CD31, and HLA-DR (Fig. 2A); consistent with a prelimi-
nary study (33). However, donor variability was seen in the
expression of additional markers not included in the ISCT
panel. These markers included growth factor receptors and
other MSC-related markers that were selected based on
recent reports highlighting their ability to identify MSCs [22,
39]. Of the additional markers, PDGFR-a and STRO-1 were dif-
ferentially expressed on the surface of high- versus low-
growth capacity MSCs, with high-growth MSCs having the
highest expression levels. We also noted that CD146 was dif-
ferentially expressed with high-growth MSCs having the high-
est expression, with the exception of low-growth MSCs from
donor F. In a similar manner, CD49a was also most highly
expressed in high-growth MSCs, with the exception of donor
E. Collectively these data highlight the utility of several addi-
tional biomarkers that may be used to further expand upon
the standard ISCT panel.
Immunosuppressive Ability of MSCs
Because MSCs are known to suppress T-cell proliferation [6,
40], we sought to determine whether this functional behavior
varied between donors with high- and low-growth capacity
MSCs. For this assay, we chose one donor with high-growth
capacity MSCs (donor A) and one donor with low-growth
capacity MSCs (donor F), based on the availability of sufﬁcient
cells for the assay. Analysis of T-cell proliferation by CFDA-
based ﬂow cytometry showed that proliferation under anti-
body stimulation was suppressed by MSCs in a dose-
dependent manner, irrespective of the donor (Fig. 2B). At a T
cell/MSC ratio of 32:1, no suppression was observed with
either MSC donor, rather the level of T-cell proliferation was
similar to that observed for antibody-stimulated T cells alone
(no MSC treatment). Notably, inhibition was strongest at a T
cell/MSC ratio of 1:2 with only 5.19% of the cultured T cells
Samsonraj, Rai, Sathiyanathan et al. 1881
www.StemCells.com VC 2015 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Figure 1. Isolation and growth characteristics of MSCs. (A): Phase-contrast images of MSCs isolated by plastic adherence. All donor
MSCs adhered to plastic and were spindle-shaped in morphology. (B): Colony-forming efﬁciency of each donor was estimated by enu-
merating the number of colonies formed per 100,000 bone marrow mononuclear cells plated. *, p< .05 ANOVA, with Tukey’s multiple
comparison test. (C): After expanding MSCs for three passages, cells with low forward scatter and low side scatter (Q1) were deter-
mined by ﬂow-cytometry. *, p< .05 ANOVA, with Tukey’s multiple comparison test. (D): Cumulative population doubling from passage 1
(P1) to passage 13 (P13) and cumulative cell number at P7 (i) and P13 (ii) were determined. Difference in growth capacity was observed
and donors grouped into those with either high- or low-growth capacity MSCs. *, p< .05, Student’s t test. (E): Changes in relative telo-
mere length from P1 to P15; data for Donor D from Samsonraj et. al., (33) was reapplied for comparison purposes. (F): Regression val-
ues for telomere loss in high- and low-growth MSCs over 15 passages. Each data point from (B) to (F) represents the mean and SD of
triplicate experiments. Abbreviations: FSC, forward scatter; MSC, mesenchymal stem cell; SSC, side scatter.
1882 Establishing Criteria for hMSC Potency
STEM CELLSVC 2015 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
proliferating (Supporting Information Table S5). At this T cell/
MSC ratio, MSCs from both donors were equally able to inhibit
T-cell proliferation (Fig. 2B; Supporting Information Fig. S2). Col-
lectively, our data show that the two donor MSCs are immuno-
suppressive, independent of their growth status. These results
align with a previous study from our lab that demonstrates
that the immunomodulation capacity of the MSCs was not
diminished, irrespective of their growth capacities [41].
Secretion Profiles of Growth Factors and
Cytokines by MSCs
Some of the regenerative capacity of MSCs has been attrib-
uted to the factors they secrete when administered to treat
disease or injury (see review [29]). To assess this function, we
assayed a set of 14 growth factors and cytokines previously
associated with key MSC functions [29] such as immunomo-
dulation (HGF and leukemia inhibitory factor (LIF)),
Figure 2. Surface phenotypic proﬁles and immunosuppression of MSCs. (A): Scatter plot of a panel of 25-cell-surface biomarkers on P4
MSCs as determined by ﬂow cytometric analysis (ﬂuorescence-activated cell sorting) from a single experiment; data for Donor E from
Samsonraj et. al., (33) was reapplied for comparison purposes. (B): Donor MSCs from high-growth capacity (donor A) and low-growth
capacity (donor F) at P4 were assayed for their immunosuppressive ability in a T-cell-based assay. Negative control5 absence of MSCs
and absence of antibody stimulation of T cells, positive control5 absence of MSCs and presence of antibody stimulation of T cells. Each
data point in (B) represents the mean and SD of triplicate experiments. Abbreviations: ISCT, International Society for Cellular Therapy;
MSC, mesenchymal stem cell.
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chemoattraction (RANTES, SDF-1a, fractalkine, MIP-1a, MCP-1,
and MCP-2), support of progenitor cells (IL-6, FGF-2, PDGF-AA,
PDGF-BB, and EGF), angiogenesis (VEGF165, FGF-2, PDGF-AA,
PDGF-BB, and EGF), antiscarring (HGF and FGF-2), and antia-
poptosis (FGF-2, HGF, and VEGF165). All donor MSCs secreted
detectable amounts of the various factors, albeit at varying
amounts (Fig. 3; Supporting Information Table S3). Data from
duplicate experiments for each donor show similar secretion
levels for each of the factors tested and are presented as a
mean value (Fig. 3; Supporting Information Tables S3, S6). Also,
for each of these factors, no difference was observed between
the high- or low-growth capacity groups (Supporting Informa-
tion Fig. S3). However, secretion levels varied from <10 pg/ml
for RANTES, MCP-2, MIP-1a, PDGF-AA, and EGF; 10–100 pg/ml
for LIF, PDGF-BB, and fractalkine; 100–1,000 pg/ml for SDF-1a,
IL-6, VEGF165, and HGF; and >1,000 pg/ml for MCP-1 and FGF-
2 (Supporting Information Table S3). It is to be noted that the
analysis of growth factor and cytokine secretion were per-
formed using cells at passage 4 at which stage the levels of
secretion between the two groups were not signiﬁcantly differ-
ent. At this passage, we did not observe signiﬁcant differences
in the growth capacity between the two groups, as can be
seen from their cumulative cells numbers (p value5 .144), pop-
ulation doubling, PD (p value5 .337), and cumulative PD (p
value5 .166) (Supporting Information Fig. S1C).
Gene Expression Analysis
To identify differences between the high- or low-growth
capacity cells at the mRNA level, qPCR was performed to
assess the levels of mesoderm-related markers TWIST-1 and
DERMO-1. High-growth capacity MSCs demonstrated signiﬁ-
cantly higher (p .05) transcript levels of these markers (Fig.
4A). A global gene expression analysis was next performed on
these two groups. A fold change cut-off of 1.5 and p .05
delineated a small set of transcripts differentially expressed
between the two groups, with 74 genes signiﬁcantly enriched
in the high-growth MSCs and 149 in the low-growth capacity
MSCs (Fig. 4B). The limited size of the distinguishing gene sets
indicates that the two groups are largely similar and that the
trait variation could be attributed to these genes.
Gene ontology analysis by DAVID functional annotation
clustering [34] was performed on the gene lists generated to
identify biological processes enriched in the high- and low-
growth MSC groups. Genes regulating cell adhesion and the
organization of cytoskeleton and organelles were signiﬁcantly
upregulated (p .05) in high-growth capacity group (Support-
ing Information Table S4A), which are indicative of a faster
rate of turnover. Adhesion to the matrix and neighboring cells
correlates with cell cycle progression [42, 43]. Genes enriched
in the low-growth MSCs tend to be cell morphogenetic and
related to the development of mesenchyme-derived organs
(Supporting Information Table S4B).
In order to investigate the upregulation/downregulation of
genes involved in MSC differentiation, we assayed for the tran-
script levels of RUNX2, BSP-II, ALP, COL2A1, SOX9, CEBPa, and
PPARc under noninduced conditions by qPCR (Fig. 4C). Individual
donors demonstrated some variability in the baseline expression
of these genes; however, no difference in these trilineage differ-
entiation markers was observed between the two groups.
Multilineage Differentiation Ability
To assess the multipotency of the MSCs from the various
donors, cells were induced to differentiate down the osteo-
genic, adipogenic, and chondrogenic lineages by culturing
them with deﬁned media components and culture conditions.
All donor MSCs demonstrated trilineage differentiation ability
(Fig. 5, Supporting Information Fig. S4). With the exception of
RUNX2, all mRNA transcripts assessed were upregulated when
MSCs were exposed to the various lineage-induction condi-
tions (Figs. 4C, 5A). Moreover, stains for bone (von Kossa),
cartilage (alcian blue), and fat (oil red O) further highlight
similarities in the in vitro differentiation capacity of high- and
low-growth MSCs (Fig. 5B, 5C) and suggests this criteria is not
sufﬁcient to distinguish between these two groups of cells.
In Vivo Ectopic Bone-Forming Efficacy of MSCs
The in vitro characterization of MSCs was followed by a func-
tional in vivo assay to determine the ability of high- and low-
growth capacity MSCs to contribute to the formation of
ectopic bone in mice over an 8-week period (Fig. 6A). MSCs
from all donors demonstrated a capacity to form ectopic
bone, albeit to varying extents. The scaffold, MASTERGRAFT
Matrix, with no MSCs produced some bone, in keeping with
the osteoconductive property of this scaffold. However, scaf-
fold seeded with high-growth capacity MSCs exhibited a sig-
niﬁcantly increased ability to form ectopic bone (p< .05)
compared with both scaffold alone or scaffold seeded with
low-growth capacity MSCs, as determined by mCT analysis
(Figs 6B–6D). Notably, no difference in the ability to form
ectopic bone was observed between scaffold alone and scaf-
fold seeded with low-growth MSCs. Histological sections taken
through the implants stained with both H&E and modiﬁed tri-
chrome permitted a more detailed assessment of tissue mor-
phology as well as the extent of ectopic bone formation
versus ﬁbrous tissue. Our data show that scaffold seeded with
high-growth MSCs (donors A, C, and E) readily produced bone
tissue that also contained increased amounts of mineral (high-
lighted by the increased red staining in the accompanying
Figure 3. Growth factor and cytokine secretion proﬁles of mes-
enchymal stem cells. Cells at P4 were grown in basal media for 4
days and secreted proteins assessed by multiplex immunoassay.
Results are expressed in logarithmic concentration as mean of
duplicate experiments. Data from the duplicate experiments are
presented in Supporting Information Table S6.
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modiﬁed trichrome sections) (Fig. 7). Further microscopic
examination of each implant highlighted areas that contained
relatively low amounts of bone tissue as well as areas with
moderate and high amounts of bone tissue. However, of par-
ticular note was the observation that scaffold seeded with
high-growth capacity MSCs contained more bone tissue
Figure 4. Gene expression analysis. (A): Quantitative PCR analysis of the mesoderm-related mRNA transcripts TWIST-1 and DERMO-1 in
high- and low-growth capacity mesenchymal stem cells (MSCs) at P4. (B): Venn diagram showing global gene expression analysis of
high-and low-growth capacity MSCs determined by microarray analysis at P4. Only transcripts with a FC 1.5 and p value <.05 were
included. (C): Quantitative PCR analysis of lineage-speciﬁc markers in P4 cells cultured for 14 days under noninduced conditions. Graphs
are represented as relative expression units compared with b-actin. Each data point represents the mean of triplicate experiments.
Abbreviations: ALP, alkaline phosphatase; BSP II, bone sialoprotein II; CEBPa, CCAAT enhancer binding protein alpha; Col2A1, collagen,
type II, alpha 1; FC, fold change; PPARc, peroxisome proliferator-activated receptor gamma; REU, relative expression units; RUNX2, Runt-
related transcription factor 2.
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Figure 5. Multilineage differentiation. Multilineage ability was determined in P4 mesenchymal stem cells. (A): Quantitative PCR analysis
of osteogenic markers RUNX2, BSP-II, and ALP, chondrogenic markers COL2A1 and SOX9, and adipogenic markers CEBPa and PPARc in
cells cultured for 14 days under the respective lineage induction conditions. Scatterplots are represented as relative expression units
compared with b-ACTIN. (B): Representative images with von Kossa, oil red O, and alcian blue staining. Scale bar5 10 mm. (C): Quantiﬁ-
cation of stains by image analysis normalized to DNA content. Each data point represents the mean of triplicate experiments. Abbrevia-
tions: ALP, alkaline phosphatase; BSP II, bone sialoprotein II; CEBPa, CCAAT enhancer binding protein alpha; Col2A1, collagen, type
II, alpha 1; PPARc, peroxisome proliferator-activated receptor gamma; REU, relative expression units; RUNX2, Runt-related transcription
factor 2.
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throughout the implant, even in areas described as having
low amounts of bone tissue, when compared with both scaf-
fold alone or scaffold seeded with low-growth capacity MSCs
that contained increased amounts of ﬁbrous tissue, which has
been represented as a color gradient bar (Fig. 7). Based on
morphological assessment of all the implant sections from dif-
ferent donors, we identify that the lowest amount of bone
tissue formed by high-growth capacity MSCs was higher than
the average amount produced by low-growth capacity donors.
We also evaluated the species origin of the new bone tissue
formed by staining with antibodies against human and mouse
osteocalcin. Our results show that the bone formed was of a
mixture of both human and mouse tissue (Supporting Infor-
mation Figs. S5, S6). Scaffolds seeded with high-growth
capacity MSCs showed relatively higher levels of human
osteocalcin staining compared to low-growth MSCs.
Figure 6. Ectopic bone formation. (Aa, Ab): Representative images of mesenchymal stem cells (MSCs)-loaded scaffolds implanted at
subcutaneous sites. (Ac): X-ray showing two MSC-loaded implants 8 weeks after implantation. (B): Panel showing representative digital
images, 2D x-rays, and mCT reconstructions of implants after 8 weeks. (C): Scatter plot showing new bone volume generated by MSC-
loaded scaffolds from each donor. Scaffold without cells (scaffold alone) was included as control. (D): Bar graph comparing volume of
new bone formation between high- and low-growth capacity MSC-loaded scaffolds; *, p< .05, Student’s t test. Each data point in (C)
represents a single experiment and each data point in (D) represents the mean and SD from the data in the scatter plot (C). Scaffold
alone n5 5, high-growth capacity MSC-loaded scaffold n5 15, low-growth capacity MSC-loaded scaffold n5 15.
Samsonraj, Rai, Sathiyanathan et al. 1887
www.StemCells.com VC 2015 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Taking into consideration all the results above, we identi-
ﬁed the following in vitro parameters that positively correlate
with in vivo bone formation: cell size (r2 value5 0.74), cumu-
lative cell number (r2 value5 0.65), STRO-1 expression (r2 val-
ue5 0.55), mRNA level of TWIST-1 (r2 value5 0.8), and mRNA
level of DERMO-1 (r2 value5 0.72). The regression plots are
provided as Supporting Information Figure S7.
DISCUSSION
To date, no systematic correlation between the properties of
MSCs in vitro and their in vivo efﬁcacy has been demon-
strated, primarily because there is no universally accepted in
vitro method for predicting the therapeutic potency of
MSCs. A key study attempting to provide clinically relevant
potency assays demonstrated that the doubling time of
Figure 7. Histological analysis of ectopic bone formation. Representative images of implant sections stained with hematoxylin & eosin
(H&E) and modiﬁed trichrome. Reading each panel from left to right are representative images of areas containing low (left) to high
(right) bone formation. Increased variability in the amount of bone tissue is observed for implants containing low-growth capacity mes-
enchymal stem cells when compared with implants containing high-growth capacity cells. Color gradient at the bottom of the ﬁgure
indicates relative changes in tissue phenotype. H&E panel: light pink represents ﬁbrous tissue and dark pink bone tissue. Modiﬁed tri-
chrome panel: pale blue represents ﬁbrous tissue and bright red, mineralized bone tissue. Scale bar5 50 mm.
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MSCs correlates with in vivo bone formation [44]; here, we
have extended that concept to include other notable in vitro
parameters that may help to better deﬁne MSC quality, such
as colony-forming efﬁciency [9], cell size [24], immunosup-
pression [40], and cytokine and growth factor secretion [29].
Indeed, a recent review by Prockop et al. [8] highlighted the
need for the benchmarking of MSCs against an established
reference MSC line. In this study, we have used a subcutane-
ous ectopic bone formation assay for assessing MSC potency,
the reason being ectopic models offer unique advantages
over orthotopic (bone) environments, including a relative
lack of bone cytokine stimulation and cell-to-cell interaction
with endogenous (host) bone-forming cells [45]. This allows
for relatively controlled in vivo experimental bone formation
and better analysis of the new bone formed. Although this
study does not address the potential potency of these cells
for other clinical applications (such as cardiac and inﬂamma-
tory conditions), our work does offer new insight into select-
ing potent MSCs using a simple ectopic bone formation
model. The data obtained from this study should facilitate
future evaluation of the varying growth capacity of MSCs
and the relationship to other clinical applications that can be
assessed using relevant preclinical models.
By comparing our in vitro ﬁndings with in vivo bone for-
mation ability, we conclude that MSCs with higher CFU-F efﬁ-
ciencies, a larger proportion of small-sized cells, and
enhanced growth capacity were able to form increased
amounts of bone at ectopic sites. Another important outcome
from this study was the need to include additional cell-
surface biomarkers in the assessment for the identiﬁcation of
MSC, thus highlighting that the ISCT panel of surface markers
did not adequately predict the in vivo potency of MSCs. Nota-
bly, in this study, the use of additional surface markers such
as STRO-1 and PDGFR-a was able to distinguish between
MSCs with high versus low ectopic bone-forming ability, and
thus may help to identify more potent MSCs. Importantly, the
expression of STRO-1 on bone marrow-derived MSCs has
been extensively studied [17, 18, 46] and our results are sup-
portive of previous investigations showing STRO-11 cells hav-
ing improved growth and colony-formation ability. More
recent studies have indicated that PDGFR-a is expressed by
nestin1 MSCs [47], and PDGFR signaling is a key regulator of
MSC potency [48]. Our ﬁnding that the high-growth capacity
MSCs (with increased bone-forming ability) also possess
higher expression levels of STRO-1 and PDGFR-a, further cor-
roborate these investigations.
Another feature of MSCs pertains to their immunomodula-
tory activities. These cells appear to have potent immune regu-
latory functions that make them good therapeutic candidates
for tissue injury and/or inﬂammation [40]. It is evident from
various studies that the mechanisms underlying MSC-mediated
immunosuppression are contact-dependent and -independent
[49–51] which include suppression of T cells [51], inhibition of
dendritic cell differentiation and B-cell proliferation [52]. Our
data support these ﬁndings and show that stimulated T-cell
proliferation can be suppressed by MSCs, so highlighting the
importance of including MSC-mediated immunosuppression in
an assessment of MSC quality. For the assessment of MSC
immunosuppression, we used puriﬁed T cells as effector cells
rather than unselected PBMCs that provide less reproducible
results owing to the indirect effect of monocytes. Our method
of studying immunosuppression is in agreement with the
recent suggestions provided by the ISCT for better evaluating
the relative functional potency of MSCs [31].
In addition to phenotypic and functional assays of MSCs
in this study, a global gene expression analysis was per-
formed. Results revealed the enrichment of proliferation-
associated processes in high-growth MSCs and maturation-
related processes in low-growth MSCs, which together suggest
a physiological basis that may underpin their phenotypic
divergence in vitro. As the MSCs were derived and propa-
gated from donors according to standardized procedures, dif-
ferences in the physiology of the cells might be due to an
underlying variation in their transcriptome. Also, increased
expression of TWIST-1 and DERMO-1, mRNA transcripts shown
by Psaltis et al. [46] to be enriched in STRO-11 MSCs and
known to be crucial for MSC growth and development, fur-
ther attests to the possible inclusion of these markers in MSC
assessment.
There is a growing acceptance that the tissue regeneration
capacity of MSCs is driven, in part, by the factors they secrete
when transplanted to sites of injury or disease [5]. However,
to the best of our knowledge, donor to donor variability has
not been reported in the levels of key regenerative growth
factors and cytokines secreted by MSCs. Among the many
growth factors regulating bone metabolism, FGF-2 and VEGF
are recognized as autocrine or paracrine factors crucial for
osteoblasts differentiation [53, 54] and angiogenesis [55],
respectively. Analysis of the expression levels in MSCs of
growth factors and cytokines important in tissue repair
showed little variability between donors, irrespective of
grouping based on growth capacity. Despite this ﬁnding,
increased amounts of ectopic bone were formed by high-
growth capacity MSCs compared to low-growth capacity
MSCs. Because the high-growth capacity MSCs lose telomeres
at slower rates, it may be possible that they are able to
undergo more divisions before senescence, thus providing an
advantage in sustaining the production of key cytokines for
longer periods of time (after transplantation), rather than the
absolute amounts they produce. Furthermore, the bone
formed was a mixture of human (donor) and mouse (host) tis-
sue suggesting that the transplanted MSCs may have differen-
tiated into osteogenic cells that deposit human tissue while
also being able to stimulate the formation of host (mouse)
bone. However, the underlying mechanism driving this host
response remains to be elucidated, particularly because this
study failed to show any difference in the in vitro secretory
levels of key osteogenic factors with passage 4 MSCs. As
growth differences became evident only after passage 7, it
would be interesting to compare cytokine secretion and their
autocrine effects on the MSCs at later passages. It is possible
that MSCs when transplanted secrete levels of reparative fac-
tors that may not be correlative with their in vitro secretions,
an area that needs further investigation.
Although both groups of MSCs secreted similar levels of
growth factors and cytokines and showed comparable capaci-
ties for osteogenic differentiation in vitro, they produced vary-
ing amounts of ectopic bone in vivo. This could be because
the high-growth MSCs were able to survive longer and have
sustained growth because of relatively longer telomeres and a
higher proportion of clonogenic small-sized cells. The deposi-
tion of bone in the scaffold suggests that the capacity to
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deposit a mineralized matrix is spatially controlled, and that the
most adaptable MSC to achieve this may be the high-growth
capacity cells. That the standard in vitro osteogenic assay yields
a poor prognosis is in accord with a previous study from our
group and others showing that ex vivo matrix mineralization
assays lack speciﬁcity, and shows little or no concordance with
true bone formation [15, 56]. We have also shown recently that
culture media containing a particular heparan sulfate glycosami-
noglycan can be used to enrich for a population of potent MSCs
with increased self-renewal, longer telomeres, and enhanced
survival and bone reparative properties when transplanted in
vivo [41]. Of particular note, data from this study show that
high-growth capacity cells shorten their telomeres at slower
rates compared with low-growth capacity MSCs and continued
to proliferate for longer periods, suggesting that they may also
have increased survival when transplanted in vivo. Support for
this is provided by the ﬁnding that high-growth capacity MSCs
stimulated greater amounts of ectopic bone formation that was
a mixture of human and mouse origin, thus suggesting that the
transplanted cells may differentiate down the osteogenic lineage
and deposit bone-like tissue as well as stimulated the host to
deposit new bone-like tissue. Similarly, decellularized extracellu-
lar matrix (ECM) substrates have proven useful for the expan-
sion of multipotent adult stem cells that are smaller in size and
more homogenous [57], thus highlighting the role of the culture
microenvironment in the maintenance of MSC potency.
Despite the immense amount of work done over the last
decade, MSCs are still a relatively poorly understood, heteroge-
nous mixture of cells with unpredictable properties. As pointed
out by Mendicino et al. in their recent review [3], there is bewil-
dering diversity in how sponsors have deﬁned, manufactured,
and described MSCs in their regulatory submissions to the U.S.
FDA, not only in terms of tissue sourcing, but also in methods
of in vitro propagation, cell-surface marker expression, and prod-
uct manufacturing. Survey of FDA submissions shows that seven
cell-surface markers are routinely used for MSC-based product
IND submissions (CD105, CD73, CD90, CD45, CD34, CD14, and
HLA class II), which is consistent with the marker set speciﬁed
by the ISCT [4]. However, it is clear that this marker set is far
from deﬁnitive, and encompasses a vast majority of cells with-
out true, “stem-like” qualities; there is still an open question as
to which particular set of markers truly describes this heteroge-
neous cell class. Here, we advocate the combined use of preclin-
ical animal studies coupled with a broader set of in vitro
characteristics that may be used to deﬁne MSC potency. More
work of this kind is needed to provide clinicians with MSCs of
the highest quality for therapeutic use.
CONCLUSION
We have identiﬁed the MSC characteristics of cell size and in
vitro growth capacity, together with expression of STRO-1,
TWIST-1 and DERMO-1 as being positively correlated with
ectopic bone-forming ability of implanted MSCs. We thus
advocate the use of such additional criteria when assessing
MSC quality before applying them as a cellular therapy.
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